This dataset contains the summary data visualizations and clinical data of IMPACT sequencing of 229 cell-free DNA (cfDNA) and associated tumor samples with matched normal from 118 patients. Clinical data includes: Cancer Type, Number of Samples Per Patient, Mutation Count, Fraction Genome Altered, Sex, Primary/Metastasis Sample Type, Collaboration Id, Gene Panel, Oncotree Code, Tumor/cfDNA Sample...

Summary from the GEO: "We report the generation and characterization of tumor organoids and PDOX derived from needle biopsies of metastatic lesions from neuroendocrine prostate cancer patients." Overall design from the GEO: "Understanding the expression profile of neuroendocrine prostate cancer tumor organoids and PDOXs."

Expression profiling by high throughput sequencing Methylation profiling by high throughput sequencing Summary: This SuperSeries is composed of the following SubSeries: GSE112786: "Molecular characterization of neuroendocrine prostate cancer organoids and PDOX by RNA-seq GSE112829: Methylation profile of neuroendocrine prostate cancer models. Both of the SubSeries concerns information neuroendocrine...

This dataset contains the summary data visualizations and clinical data from whole exome sequencing of 114 metastatic tumor/normal pairs from 81 patients. Clinical data includes: Cancer Type, Number of Samples Per Patient, Mutation Count, Fraction Genome Altered, CLONET Purity, Control Site, Disease code, Genomic Burden, Oncotree Code, Other Sample ID, Pathology Classification, Ploidy, Tumor Disease...

Summary from the GEO: "Our study represents a detailed molecular analysis of neuroenedocrine prostate cancer models" Overall design from the GEO: "Understanding the global methylation profile of tumor organoids and PDOXs." Abstract from the article on Synapse to further explain the study and the relating dataset: "A major hurdle in the study of rare tumors is a lack of existing preclinical models....

Summary from dbGap: "A subset of advanced prostate cancers can progress from an androgen receptor (AR)-driven state to AR independence, often associated with low or absent AR expression and extensive neuroendocrine differentiation. Once neuroendocrine prostate cancer (NEPC) develops, patients typically demonstrate an aggressive clinical course and poor overall survival. Early diagnosis is important...

Summary from GEO: "In lung and prostate adenocarcinomas, neuroendocrine (NE) transformation to an aggressive derivative resembling small cell lung cancer (SCLC) is associated with poor prognosis. We previously described dependency of SCLC on the nuclear transporter exportin 1. Here we explored the role of exportin 1 in NE transformation. We observed upregulated exportin 1 in lung and prostate pre-transformation...

Description from Figshare: "Supplementary Figure 1: Example of KRAS-mutated LCNEC: Illustration of NGS and histopathologic features; Supplementary Figure 2: Dot plots for total number of genomic alterations in carcinoid-like vs other LCNECs; Supplementary Figure 3: OncoPrints for chromatin modifier, neurogenesis/neural function, DNA replication/repair and PI3K-AKT-mTOR pathway genes; Supplementary...

Description from Figshare: "Supplementary Table 1: Next-generation sequencing (MSK-IMPACT) gene panel"

Description from Figshare: "Supplementary Table 2: Immunohistochemical antibodies and protocols"